Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.
The new women's health and STI tests for the BD Max platform are part of a small, focused panel approach which the firm believes will resonate with physicians and labs.
Solid MDx revenue growth was driven primarily by sales of Aptima women's health products on the Panther and Tigris platforms.
The firm said that molecular product sales were up 103 percent, driven by the launch of the Solana Group A Strep assay earlier this year.
The test detects chlamydia, gonorrhea, and trichomonas from a single patient sample.
Revenues from the company’s molecular diagnostics business grew 6 percent, driven by continued strength in sales of women's health products.
The presentations were part of a Quidel-sponsored workshop and poster sessions at the Clinical Virology Symposium in Daytona Beach, Fla.
The CE mark is for two assays covering chlamydia, gonorrhea, and trichomonas, and which run on the BD Max system.
The trichomonas assay is Quidel's sixth assay running on the AmpliVue handheld molecular diagnostic device that has been cleared by the FDA.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.